Olaparib and durvalumab in patients with germline BRCA-mutated metastatic breast cancer (MEDIOLA): an open-label, multicentre, phase 1/2, basket study

2020444 citationsJournal Article

Authors

Good health and well-being

Published in: The Lancet Oncology

Volume 21, Issue 9, pp. 1155-1164

Field-Weighted Citation Impact: 23.35